Web Exclusives

Breast cancer treatments pose significant fertility risks, emphasizing the importance of fertility counseling and preservation techniques, as highlighted by a study on young breast cancer patients. Read More ›

Adding aromatase inhibitors to ovarian function suppression significantly improves invasive disease-free survival and underscores the importance of individualized treatment decisions based on clinicopathological factors. Read More ›

The incidence of breast cancer in young women has been increasing globally, and understanding its management and prognosis is crucial due to its aggressive nature and poor outcomes. Read More ›

Adjuvant treatment options for premenopausal women with hormone receptor–positive breast cancer now include endocrine therapy and ovarian function suppression (OFS) based on clinicopathologic characteristics that determine composite risk of recurrence. Read More ›

Understanding the role of the estrogen receptor (ER) in the pathogenesis of breast cancer has led to the development of treatment options that lead to reduced estrogen levels. In addition, the expression level of ER can serve as a prognostic indicator for disease recurrence and treatment response. Read More ›

With the availability of approaches for preserving fertility and ovarian function, physicians should be prepared to discuss the impact of chemotherapy on fertility and ovarian function with patients newly diagnosed with breast cancer in order to personalize treatment plans based on patients’ goals. In the modern era, an increasing number of women are opting to delay pregnancy. Read More ›

Measuring estradiol levels during ovarian function suppression (OFS) remains debatable. It can be argued that the assessment of estradiol levels is clinically irrelevant since general OFS can be achieved with the currently available approaches, and the outcomes of OFS trials are not based on estradiol levels. However, a variety of factors may lead to ovarian escape (OE). Read More ›

Despite the fact that 51% of patients with breast cancer have reported fertility concerns, evidence indicates that fertility preservation methods are underutilized. Read More ›

Studies have demonstrated that at least half of patients undergoing treatment for breast cancer are concerned about potential infertility and demonstrate interest in becoming pregnant after the conclusion of their treatment. Even those not interested in pregnancy seek to avoid ovarian insufficiency and early menopause, which can negatively impact patients’ quality of life—an important treatment goal. Read More ›

In the United States, 2 gonadotropin-releasing hormone (GnRH) agonists, goserelin and leuprolide, are widely available for ovarian function suppression (OFS) in patients with breast cancer. The ovarian-protective effects of GnRH agonists are mediated by downregulating GnRH receptors in the pituitary gland, which suppresses the release of luteinizing hormone and follicle-stimulating hormone. Read More ›